← back to search

Abhishek A. Chakraborty

Case Western Reserve University · US
Area of research
Cancer Research · Cell Biology
Research interest
Research interests include Cancer research, Biology, Chemistry, Cell biology, Clear cell renal cell carcinoma, and Kinase.
h-index
citations
2,130
works
13
NIH funding
primary concept
email

Recent publications

The SLC1A1/EAAT3 dicarboxylic amino acid transporter is an epigenetically dysregulated nutrient carrier that sustains oncogenic metabolic programs
Nature Communications 2025cited by 2position: lastdoi
Chronic hypoxia stabilizes 3βHSD1 via autophagy suppression
Cell Reports 2024cited by 10position: middledoi
GAP43-dependent mitochondria transfer from astrocytes enhances glioblastoma tumorigenicity
Nature Cancer 2023cited by 206position: middledoi
A Mesenchymal Tumor Cell State Confers Increased Dependency on the BCL-XL Antiapoptotic Protein in Kidney Cancer
Clinical Cancer Research 2022cited by 14position: lastdoi
Histone demethylase KDM6A directly senses oxygen to control chromatin and cell fate
Science 2019cited by 433position: firstdoi
Mutant p53 induces a hypoxia transcriptional program in gastric and esophageal adenocarcinoma
JCI Insight 2019cited by 34position: middledoi
Transaminase Inhibition by 2-Hydroxyglutarate Impairs Glutamate Biosynthesis and Redox Homeostasis in Glioma
Cell 2018cited by 364position: middledoi
Cells Lacking the <i>RB1</i> Tumor Suppressor Gene Are Hyperdependent on Aurora B Kinase for Survival
Cancer Discovery 2018cited by 176position: middledoi
HIF activation causes synthetic lethality between the <i>VHL</i> tumor suppressor and the <i>EZH1</i> histone methyltransferase
Science Translational Medicine 2017cited by 46position: firstdoi
On-target efficacy of a HIF-2α antagonist in preclinical kidney cancer models
Nature 2016cited by 457position: middledoi
pVHL suppresses kinase activity of Akt in a proline-hydroxylation–dependent manner
Science 2016cited by 208position: middledoi
EGLN1 Inhibition and Rerouting of α-Ketoglutarate Suffice for Remote Ischemic Protection
Cell 2016cited by 143position: middledoi
A common functional consequence of tumor-derived mutations within c-MYC
Oncogene 2014cited by 37position: firstdoi

Grants

No grants ingested yet.

Frequent collaborators

William G. Kaelin · Harvard University7 papers (2016–2022)Sabina Signoretti · Cancer Research Center4 papers (2016–2019)Jacob D. Jaffe · Massachusetts Institute of Technology2 papers (2017–2019)Jesse Novak · Howard Hughes Medical Institute2 papers (2016–2017)Amanda L. Creech · APLA Health2 papers (2017–2019)Benjamin A. Olenchock · Massachusetts Institute of Technology2 papers (2016–2019)Samuel K. McBrayer · Dana-Farber Brigham Cancer Center2 papers (2017–2019)Francisca Vázquez · Universidade de Santiago de Compostela1 papers (2022–2022)William P. Tansey · California Institute of Technology1 papers (2014–2014) · 1 papers (2019–2019)Ella Liberzon · Biogen (United States)1 papers (2016–2016)Marcia C. Haigis · Harvard University1 papers (2019–2019)Rebecca B. Jennings · Stony Brook Medicine1 papers (2019–2019)Yaoyu E. Wang · DeepBiome Therapeutics (United States)1 papers (2017–2017) · 1 papers (2019–2019)Clary B. Clish · Broad Institute1 papers (2016–2016)Alison E. Ringel · Massachusetts Institute of Technology1 papers (2019–2019)Ameeta Kelekar · University of Minnesota, Twin Cities1 papers (2016–2016)Glenn S. Cowley · Massachusetts Institute of Technology1 papers (2017–2017)Min Yuan · Tongji University1 papers (2016–2016)